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Abstract 
Objectives: To study risk for cardiovascular disease (CVD) in Japanese patients with rheumatoid arthritis (RA).
Methods: We used a Medical Data Vision database mainly composed of health insurance claim data and diagnosis-
procedure combination data from Japan. Patients with RA diagnosed from April 2011 to March 2014 at 71 hospitals 
were identified with the International Classification of Diseases 10th revision (ICD-10) and history of anti-RA drug 
prescription. Hospitalizations for CVD including ischemic heart disease, heart failure, and stroke were identified by a 
combination of diagnosis (ICD-10) and diagnostic procedures. CVD incidence rate ratio (IRR) for RA versus osteoarthri-
tis was calculated. Risk factors were analyzed using univariate and multivariate Cox proportional hazard models with 
baseline C-reactive protein (CRP) and traditional risk factors as covariates.
Results: We identified 8658 patients with RA. The age–sex adjusted IRR for RA versus osteoarthritis was high for total 
CVD [2.12; 95 % confidence interval (CI) 1.93–2.32], ischemic heart disease (2.16; 95 % CI 1.86–2.50), heart failure (2.34; 
95 % CI 2.07–2.65), and stroke (1.68; 95 % CI 1.41–2.00). Risk factor analysis showed a tendency for cardiovascular risk 
to increase with higher baseline CRP, although the difference was not statistically significant (hazard ratio 1.43; 95 % CI 
0.99–2.07).
Conclusion: Our study indicates an increased risk for CVD and an association between systemic inflammation and 
CVD in Japanese RA patients.
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Background
Rheumatoid arthritis (RA) is a chronic disease with 
various complications and a higher mortality than that 
expected in the general population (Pincus et  al. 1994). 
Cardiovascular disease (CVD) is one of the serious com-
plications in RA and is a major cause of death in RA 
patients in both the West and Japan (Sihvonen et  al. 
2004; Nakajima et  al. 2010). Non-clinical research has 
suggested that proinflammatory cytokines, which are 
present at higher levels in RA patients, play a role in the 
development of CVD (Libby 2008). Moreover, a correla-
tion between increased levels of inflammatory marker 
C-reactive protein (CRP) and higher incidence of CVD 
has been observed in an epidemiological study (Goodson 
et al. 2005).
A higher CVD risk in RA patients has been observed 
in some epidemiological studies in Western countries 
(Maradit-Kremers et al. 2005; Avina-Zubieta et al. 2008; 
Peters et  al. 2009). Although there is a known ethnic 
difference in CVD incidence in the general population 
(Menotti et  al. 1993), few studies have explored CVD 
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in RA patients in Japan. Recently, Sakai et  al. (2016) 
reported high prevalence of cardiovascular comorbidities 
in patients with RA, using a database of medical claims 
from employment-based health insurance organizations 
in Japan. We used another healthcare database of diagno-
sis-procedure combination data, health insurance claims 
data, and laboratory data from hospitals located through-
out Japan to study the relative risk of CVD as well as the 
association between systemic inflammation and CVD in 
Japanese patients with RA. Patients with osteoarthritis 
(OA) were used for comparison because inflammation is 
mostly confined to the affected joints in OA but is sys-
temic in RA. OA also shares with RA both traditional and 
lifestyle risk factors for CVD (Pelletier et al. 2001).
Methods
Data source
The healthcare database used for this study was pro-
vided by Medical Data Vision Co., Ltd. The database con-
tains Japanese diagnosis-procedure combination data 
and health insurance claims data from hospitals located 
throughout Japan, anonymously managed to protect 
patient’s personal information; some hospitals also pro-
vide laboratory data. This study used clinical data from 
71 hospitals collected from April 2011 to March 2014, 
including laboratory data from 14 hospitals.
Patients
Data were extracted for patients aged 18  years or older 
with RA or OA diagnosed for the first time during 
the study period, from April 2011 to March 2014, and 
with data available for a follow-up period of at least 
90 days (Fig. 1). The following codes from International 
Classification of Diseases 10th revision (ICD-10) were 
used to identify cases for extraction: M05, M06.0, M06.2, 
M06.3, M06.8, and M06.9 for RA, and M179 for OA. 
Each patient was prescribed or had a treatment history 
of anti-RA drugs (DMARDs, oral corticosteroids, biolog-
ics, or oral NSAIDs) or OA treatments (oral or topical 
NSAIDs, hyaluronic acid injections, or corticosteroids 
injections) and was followed up until the end of March 
2014 or until leaving the database. RA and OA patients in 
the sub-cohort were defined as patients with laboratory 
data for risk factor analyses.
Outcomes
Outcomes are defined as events that occurred after first 
diagnosis of RA or OA and were identified by a com-
bination of diagnoses (ICD-10) leading to hospitaliza-
tion and medical tests. Diagnoses of CVD in this study 
were defined as ischemic heart disease [angina pectoris 
(I20) or myocardial infarction (I21, I22)], heart failure 
(I50), and stroke [cerebral infarction (I63), intracer-
ebral hemorrhage (I61), or subarachnoid hemorrhage 
(I60)]. Medical tests used to identify ischemic heart 
disease and heart failure were electrocardiogram and 
echocardiograph. Medical tests used to identify stroke 
were computed tomography and magnetic resonance 
imaging.
Statistical analysis
Incidence rates in each cohort were calculated as the 
number of cases per total period at risk for CVD. Crude 
and age–sex adjusted incidence rate ratios (IRRs) with 
95 % confidence intervals (CIs) versus OA were also cal-
culated on the assumption of a Poisson distribution.
Excluded patients: N=3,370
• Less than 90 days of follow-up :N=3,334
• Patients under 18 years old : N=48
With first diagnosis for RA and 
treatment history of RA during the study 
period
N=12,028
Patients visit at study hospitals in the database from April 1st,
2011 to March 31st, 2014
N=3,477,160
With first diagnosis for OA and 






(Patients with laboratory data)
N=2,472
Excluded patients: N=14,254
• Less than 90 days of follow-up :N=14,199
• Patients under 18 years old : N=103
OA cohort
N=32,202
Fig. 1 Flow chart of the study cohort. RA rheumatoid arthritis, OA osteoarthritis
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Univariate and multivariate Cox-regression analyses 
were performed, including hazard ratios (HRs), 95 % CIs, 
and Wald test P values to evaluate risk factors for CVD in 
RA patients. The candidate covariates were age, sex, CRP 
at baseline, total cholesterol at baseline, and diabetes 
complications. CRP was selected as an index of systemic 
inflammation associated with RA. Total cholesterol and 
diabetes complications were selected as traditional risk 
factors for CVD. CRP and total cholesterol at baseline 
were measured on the date of or before first diagnosis of 
RA or OA. No variable selection techniques were used in 
multivariate Cox-regression analyses. Statistical analyses 
were performed using SAS version 9.3.
Ethics approval
Our study was approved by the institutional review 
board of the Public Health Research Foundation (http://
www.phrf.jp/) on 5 November 2014 and was conducted 
according to the local ethical guidelines for epidemiologi-
cal research. Informed consent was waived by the insti-
tutional review board because the database used in this 
study is anonymously managed and includes no personal 
information.
Results
A total of 8658 patients with RA (the RA cohort) and 
32,202 patients with OA were identified. Laboratory data 
for analyzing risk factors were available for 2472 patients 
with RA (the RA sub-cohort). Patients with RA were 
younger and less likely to have diabetes complications 
than patients with OA (Table  1). Sex distribution and 
total cholesterol at baseline were similar in both groups.
In the RA cohort (n = 8658), the age-sex adjusted IRRs 
for RA versus OA were statistically high for total CVD 
(2.12; 95  % CI 1.93–2.32), ischemic heart disease (2.16; 
95 % CI 1.86–2.50), myocardial infarction (3.62; 95 % CI 
2.52–5.18), heart failure (2.34; 95  % CI 2.07–2.65), and 
stroke (1.68; 95 % CI 1.41–2.00) (Table 2).
In univariate analysis of the RA sub-cohort (n = 2472), 
HRs showed that higher age (8.50; 95  % CI 5.13–14.09) 
and higher CRP (2.00; 95  % CI 1.39–2.88) at baseline 
significantly increased the risk for CVD, but no statisti-
cal significance was observed for sex, total cholesterol at 
baseline, and diabetes complications (Table  3). In mul-
tivariate analysis, we excluded total cholesterol at base-
line from the covariates because approximately half of 
patients had no baseline total cholesterol data. Adjusted 
HRs based on the multivariate model presented in 
Table  3 showed that higher age is an independent risk 
factor for CVD (HR 8.52; 95  % CI 4.76–15.23). Higher 
baseline CRP showed a trend of increasing CVD risk, 
although the difference was not statistically significant 
(HR 1.43; 95 % CI 0.99–2.07). No significant differences 
were observed for sex or diabetes complications. The 
median baseline CRP level in patients with CVD events 
(1.6  mg/dl) was higher than in patients without CVD 
events (0.7 mg/dl). In addition, the median CRP level at 
CVD onset (1.7 mg/dl) had not decreased from baseline.
Discussion
CVD can be a fatal complication in RA patients, and 
understanding CVD risk in Japanese RA patients is 
important for risk management. High prevalence of car-
diovascular comorbidities in patients with RA in Japan 
was recently shown, using a database of medical claims 
from employment-based health insurance organizations 
(Sakai et  al. 2016). However, this database covers only 
company employees and their dependents, who are con-
sidered to be younger and at lower risk for CVD than the 
retired population. We used a database that includes data 
on patients of all ages from hospitals located throughout 
Japan.
Table 1 Characteristics of the study populations
RA rheumatoid arthritis, OA osteoarthritis, SD standard deviation, CRP C-reactive protein
a Patients with laboratory data who were included in risk factor analysis
Characteristics RA patients OA patients
All cohort Sub-cohorta
Number of patients, n 8658 2472 32,202
Female, n (%) 5819 (67.2) 1711 (69.2) 22,046 (68.5)
Age, mean (SD) (years) 63.8 (15.1) 62.4 (15.3) 70.3 (12.0)
 Median (years) 66.0 64.0 72.0
Diabetes complications, n (%) 424 (4.9) 90 (3.6) 2571 (8.0)
CRP at baseline, mean (SD) (mg/dl) – 2.4 (4.1) –
 Median (mg/dl) – 0.7 –
Total cholesterol at baseline, mean (SD) (mg/dl) – 186.9 (39.9) –
 Median (mg/dl) – 183.0 –
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Our study shows increased risk for CVD in RA 
patients. Adjusted IRRs for RA versus OA were 2.12 
(95 % CI 1.93–2.32) for total CVD, 2.16 (95 % CI 1.86–
2.50) for ischemic heart disease, 3.62 (95 % CI 2.52–5.18) 
for myocardial infarction, and 1.68 (95  % CI 1.41–2.00) 
for stroke. The IRR for ischemic heart disease in this 
study was similar to the odds ratio (RA vs. non-RA popu-
lation) for ischemic heart disease recently reported from 
another study in Japan (Sakai et  al. 2016), and the IRRs 
for myocardial infarction and stroke in this study were 
similar to the odds ratios (RA vs. non-RA population) for 
myocardial infarction and stroke observed in a US study 
(Solomon et al. 2006).
Our results are the first to show an association between 
systemic inflammation and CVD in Japanese patients 
with RA. The risk factor analyses identified advanced 
age as a risk factor for CVD in RA patients. The results 
also suggest that higher baseline CRP increases CVD risk 
whereas higher total cholesterol at baseline, one of the 
traditional risk factors for CVD, does not. The baseline 
CRP level in patients with CVD events was higher than 
in patients without CVD events, and CRP level at CVD 
onset had not decreased from baseline. These results 
imply an association between systemic inflammation in 
RA and risk for CVD, which is consistent with previous 
reports (Goodson et al. 2005). Active treatment to reduce 
systemic inflammation may be one way to reduce CVD 
risk.
It is important to note the limitations of this study. 
First, the database for this study only covers some of the 
acute care hospitals in Japan. Therefore, the results in this 
study might not represent all RA patients in Japan. Sec-
ond, we could not follow patients over the long term. The 
median follow-up period for RA patients in the database 
was 438 days, which is shorter than in other studies. In 
spite of this short follow-up period, we observed a higher 
risk for CVD in RA patients than in OA patients. Third, 
information could not be obtained from transferring 
or recipient hospitals. Therefore, outcome information 
might be missing for some patients. Last, the database 
used does not include some of the essential patient back-
ground data for traditional CVD risk factors such as 
Table 2 Incidence rate ratios of cardiovascular disease
RA rheumatoid arthritis, OA osteoarthritis, PYs patient-years, IRR incidence rate ratio, CI confidence interval, CVD cardiovascular disease
a Adjusted by age and sex
RA patients (N = 8658) OA patients (N = 32,202) RA versus OA
Events PYs at risk Events PYs at risk Crude IRR (95 % CI) Adjusted IRRa (95 % CI)
CVD (total) 673 10,946 1633 43,304 1.63 (1.49–1.78) 2.12 (1.93–2.32)
 Ischemic heart disease 260 11,280 586 44,091 1.73 (1.50–2.01) 2.16 (1.86–2.50)
  Myocardial infarction 53 11,481 71 44,574 2.90 (2.03–4.14) 3.62 (2.52–5.18)
  Angina pectoris 224 11,319 528 44,138 1.65 (1.41–1.93) 2.05 (1.75–2.40)
 Heart failure 358 11,234 808 44,003 1.74 (1.53–1.97) 2.34 (2.07–2.65)
 Stroke 177 11,396 513 44,286 1.34 (1.13–1.59) 1.68 (1.41–2.00)
  Cerebral infarction 136 11,433 431 44,327 1.22 (1.01–1.48) 1.56 (1.29–1.90)
  Intracerebral hemorrhage 32 11,506 77 44,599 1.61 (1.07–2.43) 1.85 (1.22–2.81)
  Subarachnoid hemorrhage 15 11,517 15 44,626 3.87 (1.89–7.93) 4.45 (2.13–9.26)
Table 3 Risk factors for cardiovascular disease in RA patients estimated by univariate and multivariate Cox proportional 
hazard regression model
RA rheumatoid arthritis, CRP C-reactive protein
a Total cholesterol at baseline was excluded from covariates in the multivariate model because there was no significant association between total cholesterol and CVD 
as well as a high proportion of missing data
Univariate model Multivariate model
Hazard ratio (95 % CI) P value Hazard ratio (95 % CI) P value
Male 1.07 (0.76–1.51) 0.6812 1.02 (0.70–1.49) 0.8990
Age ≥65 years 8.50 (5.13–14.09) <0.0001 8.52 (4.76–15.23) <0.0001
CRP at baseline ≥1.0 mg/dl 2.00 (1.39–2.88) 0.0002 1.43 (0.99–2.07) 0.0564
Total cholesterol at baseline ≥220 mg/dla 0.68 (0.34–1.38) 0.2883 – –
Diabetes complications 1.86 (0.98–3.54) 0.0577 1.72 (0.83–3.56) 0.1436
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history of CVD, body mass index, blood pressure, and 
smoking history, so we could not exclude from analysis 
the confounding bias of these factors. Despite these limi-
tations, this large-scale database study presents valuable 
information to help characterize the risk for CVD in Jap-
anese patients with RA.
Conclusion
In conclusion, our study indicates an increased risk for 
CVD and an association between systemic inflammation 
and CVD in patients with RA in Japan. Further epidemi-
ological investigations in Japan could be expected to sup-
port these results.
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